Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
作者信息
Sambin Sara, Lavisse Sonia, Decaix Caroline, Pyatigorskaya Nadya, Mangone Graziella, Valabrègue Romain, Arnulf Isabelle, Cormier Florence, Lesage Suzanne, Lehericy Stephane, Remy Philippe, Brice Alexis, Corvol Jean-Christophe
机构信息
Institut du Cerveau - Paris Brain Institute - ICM, Sorbonne University, INSERM, CNRS, Paris, 75013, France.
Centre d'Investigation Clinique Neurosciences, Department of Neurology, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, 75013, France.
出版信息
Mov Disord. 2022 Feb;37(2):428-430. doi: 10.1002/mds.28833. Epub 2021 Oct 20.
PMID:34668587
Abstract
摘要
相似文献
1
Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.LRRK2基因R1441H突变家族中帕金森病转化前九年的代偿机制
Mov Disord. 2022 Feb;37(2):428-430. doi: 10.1002/mds.28833. Epub 2021 Oct 20.
2
Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.野生型亮氨酸重复激酶2作为特发性帕金森病的一个新的潜在治疗靶点。
Mov Disord. 2018 Dec;33(12):1876. doi: 10.1002/mds.27509. Epub 2018 Nov 19.
3
Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).生成 14 条与帕金森病相关的富亮氨酸重复激酶 2（LRRK2）的同基因细胞系。
Stem Cell Res. 2021 May;53:102354. doi: 10.1016/j.scr.2021.102354. Epub 2021 Apr 15.
4
LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.LRRK2 G2019S 突变抑制帕金森病体外模型中 α-突触核蛋白的降解。
Curr Med Sci. 2018 Dec;38(6):1012-1017. doi: 10.1007/s11596-018-1977-z. Epub 2018 Dec 7.
5
Functional properties of LRRK2 mutations in Taiwanese Parkinson disease.台湾帕金森病中LRRK2突变的功能特性
J Formos Med Assoc. 2017 Mar;116(3):197-204. doi: 10.1016/j.jfma.2016.04.009. Epub 2016 Jul 14.
6
LRRK2 mutations in Basque patients with Parkinson's disease.患有帕金森病的巴斯克患者中的LRRK2基因突变
Lancet Neurol. 2008 Oct;7(10):866-7; author reply 867. doi: 10.1016/S1474-4422(08)70204-7.
7
Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.在以北美为基础的家族性帕金森病样本中，除G2019S外，LRRK2基因的其他突变很少见。
Mov Disord. 2006 Dec;21(12):2257-60. doi: 10.1002/mds.21162.
8
Association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease.巴西一个帕金森病家族中LRRK2与GBA突变的关联
Parkinsonism Relat Disord. 2015 Jul;21(7):825-6. doi: 10.1016/j.parkreldis.2015.03.029. Epub 2015 May 2.
9
LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.亮氨酸重复激酶2：弥合散发性和遗传性帕金森病之间的差距
Lancet Neurol. 2008 Jul;7(7):562-4. doi: 10.1016/S1474-4422(08)70118-2. Epub 2008 Jun 6.
10
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.富含亮氨酸重复激酶 2 突变与帕金森病：三个问题。
ASN Neuro. 2009 Apr 14;1(1):e00002. doi: 10.1042/AN20090007.
引用本文的文献
1
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.LRRK2 基因突变在帕金森病中的作用概述。
Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845.
2
Molecular Imaging in Parkinsonian Disorders-What's New and Hot?帕金森病相关疾病中的分子影像——新热点有哪些？
Brain Sci. 2022 Aug 27;12(9):1146. doi: 10.3390/brainsci12091146.
Zotero 插件